Kannan Natarajan, senior vice president at Pfizer, discusses the potential of generative AI to streamline pharmaceutical documentation processes and improve efficiency, what he’s learned about implementing AI solutions, and the cultural challenges of adopting new technologies.

Vinod Das, Pharma R&D, Drug Innovation & AI Scouting for Bayer; sits down with Nagaraja Srivatsan to discuss the integration of generative AI in drug discovery and clinical development. He discusses the journey of AI adoption, the importance of prompt engineering, and the complexities of implementation.

Vijayalakshmi Ramshankar, professor and head of the Department of Cancer Biology and Molecular Diagnostics at Cancer Institute (WIA) sits down with Nagaraja Srivatsan to discuss the cancer research landscape in India, the work she is doing to leverage AI to improve diagnosis and outcomes, and the future of AI in oncology

Manoranjan Das, director of global drug development IT for Bristol Myers Squibb, sits down with Nagaraja Srivatsan to discuss his work to implement AI in clinical development, the importance of change management, and the lessons learned from various AI projects he’s led.

Aman Thukral, director of Clinical Systems And Digital Operations at AbbVie, sits down with Nagaraja Srivatsan to discuss the evolving landscape of clinical trials with the integration of AI, why change management is essential for successful implementation, and the need for a long-term investment approach in AI initiatives.

Tobias Guennel, senior vice president of product innovation and co-founder of QuartzBio, joins Nagaraja Srivatsan to discuss his insights on leveraging AI and advanced analytics to improve clinical trial efficiency, the integration of AI in precision medicine, and the use of AI agents to automate clinical trial operations.

Bhaskar Sambasivan, CEO of Saama, sits down with Nagaraja Srivatsan to discuss the transformative role of AI in clinical development, why AI adoption will be a CEO mandate, and why the future of AI in drug development will be about autonomous decision-making.

Mike Nally, CEO of Generate Biomedicines, sits down with Amar Drawid to discuss the innovative use of generative AI in drug discovery, how the company’s platform integrates machine learning with biological engineering to create new therapeutic proteins, and the potential of generative AI to create more effective therapies for cancer and infectious diseases.

Kannan Raman of Amazon Web Service sits down with Amar Drawid to discuss the role of AI in transforming life sciences and the importance of data strategy being tied to business outcomes. They explore the challenges of data strategy, the importance of cultural shifts within organizations, and the monetization of data as a product.

The increasing demand for AI talent in the life sciences industry is presenting a challenge for biopharma HR departments. Companies must compete for skilled workers not only against their competitors but also against tech firms that often offer more attractive compensation packages. Steve Swan, CEO of The Swan Group, sat down with Amar Drawid to discuss the current recruitment landscape for AI talent in the life sciences sector, the challenges companies are encountering, and why the mission of drug developers might give them a competitive advantage over tech companies in appealing to certain candidates.